The GLA gene makes an enzyme that breaks down certain fatty materials inside cells. This gene helps your body clear a substance called GL-3; if it does not work well, that material can build up and affect nerves, skin, kidneys, the heart, and blood vessels. Pathogenic variants in the GLA gene are linked to Fabry disease. Some people notice burning pain in the hands and feet, while others are first diagnosed after kidney or heart problems.
What is a gene?
Genes are sections of DNA that carry instructions your cells use to make molecules or regulate processes in the body. Some genes provide the information needed to produce proteins, the parts of cells that do the work. Others mainly help determine when certain processes happen, where they happen, and how strongly they run. Together, genes affect how the body develops and functions, and they can also shape how you respond to food, stress, or medications. For a deeper look at this topic, you can find more in the LearnHub.
Overview
GLAGene function
What if the gene works
The GLA gene helps make alpha-galactosidase A, an enzyme that breaks down certain fatty substances inside cells. This supports your cells’ recycling system and helps prevent buildup, especially in the kidneys, heart, and nerves.
Risk
What if the gene does not work
When the GLA gene does not work properly, fatty material builds up in cells and can cause Fabry disease. Symptoms may include pain, skin spots, and kidney or heart problems. Variants range in severity and may change onset and symptoms.
Treatment
What does that mean for your treatment
Pathogenic variants in the GLA gene can guide use of enzyme replacement therapy or, for specific amenable variants, the oral chaperone migalastat. Loss-of-function variants that are not amenable to migalastat are generally managed with enzyme replacement rather than chaperone therapy. Treatment timing and choice also take symptoms and organ involvement into account.
Conditions associated with GLA
Gene function
What if the gene works
Your cells use the GLA gene to make an enzyme that helps break down certain fatty materials after they have done their job. Understanding what the GLA gene does in the body helps show how cells carry out everyday cleanup and recycling. This work happens in lysosomes, small compartments that act like the cell’s recycling centers.
The GLA gene makes alpha-galactosidase A, an enzyme that cuts apart specific fat-sugar molecules. One of its main targets is globotriaosylceramide, often shortened to Gb3.
This enzyme works inside lysosomes (the cell’s recycling centers). It helps cells clear used glycolipids so their parts can be processed and reused in a controlled way.
Many cell types rely on this steady cleanup step as part of normal daily function. By keeping certain lipids at balanced levels, the GLA gene supports routine cell maintenance across the body.
What is a variant?
A genetic variant is a minor change in a gene’s DNA sequence. These changes are common and are part of normal human diversity, including differences in appearance, metabolism, and the way the body responds to environmental influences. Many variants do not produce any noticeable effect and simply represent natural genetic variation. In some situations, though, a variant changes how a gene works more significantly and can contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the GLA gene can change the shape, stability, or amount of the alpha-galactosidase A enzyme, so cells break down certain fatty substances less effectively. Milder variants may leave some enzyme activity, while more severe variants can sharply reduce it or stop it altogether. This range helps explain how GLA gene variants affect enzyme activity and why Fabry disease may appear later and more mildly in some people, but earlier and with broader features in others.
How variants are linked to conditions
Pathogenic variants in the GLA gene cause Fabry disease. In GLA gene variants and Fabry disease, the effects can range from childhood burning pain in the hands and feet to kidney disease, heart thickening, hearing loss, and higher stroke risk later in life. Severity varies, and people assigned female at birth can also have clear symptoms.
A variant is not necessarily a diagnosis
Variants in DNA are common across the population and are a usual part of human biology. Most do not directly affect health and instead reflect natural variation among people. For many genes, having a variant associated with a condition points to a possible link, not a certain diagnosis, particularly when more than one gene and environmental influences play a role. Still, in some situations, one well-characterized variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For GLA, risk is mainly determined by whether you inherited a disease-causing variant. Males often develop symptoms earlier and more severely, while females can have anything from mild symptoms to serious health problems. There is not enough evidence to say lifestyle changes lower this genetic risk, but early follow-up can help catch kidney, heart, and nerve problems sooner.
Inheritance of GLA variants
The inheritance of the GLA gene variants is usually X-linked because the GLA gene sits on the X chromosome. A mother carrying a disease-causing variant can pass it to sons or daughters, while a father with the variant passes it to all daughters and to none of his sons. Because females have two X chromosomes and males have one, the effects can vary, and some females may also have clear symptoms. This pattern is best known in GLA-related Fabry disease.
What does my GLA result mean for my family?
GLA-related Fabry disease is usually passed through families in an X-linked pattern, so close relatives may also carry the same gene change. Parents, brothers, sisters, and children can each have a chance of having it, though symptoms can differ a lot even within one family. In some families, women with the variant have mild symptoms, while others have more noticeable kidney, heart, or nerve problems.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the GLA gene, GLA genetic testing for Fabry disease uses a blood or saliva sample to read the gene’s DNA code. It can confirm a diagnosis in many people and can check whether relatives carry the same family variant. Results usually classify a change as pathogenic, likely pathogenic, benign, likely benign, or uncertain.
When should I consider getting a genetic test?
Consider testing for changes in the GLA gene if you or a close relative has Fabry disease, or if there are signs that fit it, such as burning pain in the hands and feet, kidney disease, heart thickening, or stroke at a young age. Testing can also help clarify risk for other family members.
A genetic result is only one part of your health story
A genetic result can provide useful insight, but how informative it is varies with the condition and the kind of variant involved. Over time, many factors, including lifestyle, environment, age, and medical history, also shape how the body functions. For some conditions, particularly those affected by many genes, genetic information offers context rather than certainty and is best considered together with other parts of care. In other situations, a genetic result may give a clear answer. In areas like medication response, genetic results can help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how your body responds to medicines. Small differences in genes can change how a drug is absorbed, broken down, or moved through the body, so the same treatment may work well for one person but less well for another. This is common and can influence both how much benefit a medicine provides and how sensitive someone is to side effects.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in a person’s genes shape the way they respond to medicines. It studies links between genes and medications to clarify why the same treatment can affect people in different ways. With many drugs, genes influence how strongly a medicine works or how the body handles it. This information can support better informed, more personalized treatment choices. More detail on this subject is available in the LearnHub.
Drugs influenced by the GLA gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in routine medication prescribing, so general questions about medicines or side effects are best discussed with your doctor. For GLA, specialists may review the exact gene change in people with Fabry disease because some changes can affect whether a treatment called migalastat is likely to help.
History
Fabry disease, the condition linked to the GLA gene, was first described in 1898 by two physicians working independently, Johannes Fabry in Germany and William Anderson in England. Initially understood only through visible traits, later recognized as tied to a specific gene, the condition was long identified by its skin findings, pain episodes, and kidney and heart complications. From these first observations, research expanded steadily. In the late 20th century, scientists mapped the GLA gene to the X chromosome and showed that harmful variants in this gene were the inherited cause. That discovery helped families move from a symptom based label to genetic confirmation. It also opened the way for more accurate family tracing and modern treatment development.